They physically block the receptor from interacting with G proteins, which terminates signaling
Body composition analyses from clinical studies indicate that a portion of weight lost may be lean mass rather than fat mass
GLP-1 agonists also reduced headache risk, with the most significant effect at 3 months (RR: 0.69), remaining statistically significant at 6, 12, and 24 months
Overall, treatment with semaglutide was associated with a reduction in the studys composite outcomecardiovascular death, nonfatal myocardial infarction or nonfatal strokeof 20% compared to a placebo, and it was linked to a safe and well-tolerated profile. SELECT trial results were published in the New England Journal of Medicine in November
55 A systematic review and meta-analysis of 7 RCTs was done to see the efficacy and safety of orforglipron and danuglipron in the treatment of T2DM and obesity